西亚试剂优势供应上万种化学试剂产品，欢迎各位新老客户咨询、选购！
中国
联系我们
联系方式：400-990-3999 / 邮箱：sales@xiyashiji.com
西亚试剂 —— 品质可靠，值得信赖
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs
Gabsang Lee1, Eirini P. Papapetrou2, Hyesoo Kim1, Stuart M. Chambers1, Mark J. Tomishima1,2,3, Christopher A. Fasano1, Yosif M. Ganat1,6, Jayanthi Menon4, Fumiko Shimizu4, Agnes Viale5, Viviane Tabar2,4, Michel Sadelain2 & Lorenz Studer1,2,4
1 Developmental Biology Program,
2 Center for Cell Engineering,
3 SKI Stem Cell Research Facility,
4 Department of Neurosurgery,
5 Genomics Core Facility, Sloan-Kettering Institute, 1275 York Ave,
6 Weill Cornell Graduate School, New York, New York 10065, USA
The isolation of human induced pluripotent stem cells (iPSCs)1, 2, 3 offers a new strategy for modelling human disease. Recent studies have reported the derivation and differentiation of disease-specific human iPSCs4, 5, 6, 7. However, a key challenge in the field is the demonstration of disease-related phenotypes and the ability to model pathogenesis and treatment of disease in iPSCs. Familial dysautonomia (FD) is a rare but fatal peripheral neuropathy, caused by a point mutation in the IKBKAP 8 gene involved in transcriptional elongation9. The disease is characterized by the depletion of autonomic and sensory neurons. The specificity to the peripheral nervous system and the mechanism of neuron loss in FD are poorly understood owing to the lack of an appropriate model system. Here we report the derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons. Gene expression analysis in purified FD-iPSC-derived lineages demonstrates tissue-specific mis-splicing of IKBKAP in vitro. Patient-specific neural crest precursors express particularly low levels of normal IKBKAP transcript, suggesting a mechanism for disease specificity. FD pathogenesis is further characterized by transcriptome analysis and cell-based assays revealing marked defects in neurogenic differentiation and migration behaviour. Furthermore, we use FD-iPSCs for validating the potency of candidate drugs in reversing aberrant splicing and ameliorating neuronal differentiation and migration. Our study illustrates the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.
